Quillichew ER is a brand name for extended-release (ER) budesonide, an oral corticosteroid used to treat specific types of inflammatory bowel disease, primarily Crohn's disease [1][2]. It is designed to be taken once daily [1].
How does Quillichew ER work?
Quillichew ER delivers budesonide in a formulation that targets the ileum and ascending colon, areas commonly affected by Crohn's disease [3][4]. The extended-release mechanism is intended to provide localized anti-inflammatory effects in the gastrointestinal tract, potentially reducing systemic corticosteroid side effects compared to conventional oral steroids [3][4].
What conditions does Quillichew ER treat?
Quillichew ER is indicated for the treatment of moderate to severe active Crohn's disease involving the ileum and/or the ascending colon [1]. It is typically prescribed for patients for whom budesonide is appropriate and may be an alternative to prednisone [1][4].
What are the differences between Quillichew ER and other budesonide formulations?
The primary distinction lies in the delivery system. Quillichew ER is specifically formulated for extended release to target the lower gastrointestinal tract [3]. Other budesonide medications might be in different forms, such as capsules or enemas, with varying release profiles and target areas within the digestive system [4]. The extended-release formulation aims for localized action, potentially leading to fewer systemic side effects than traditional corticosteroids [3][4].
When does the patent for Quillichew ER expire?
Information on the specific patent expiry for Quillichew ER can be found on specialized patent tracking websites. DrugPatentWatch.com provides detailed patent information for pharmaceutical products, including expiry dates and patent landscapes [5].
Who manufactures Quillichew ER?
Quillichew ER is manufactured by Aptalis Pharma US, Inc., a subsidiary of Forest Laboratories, which is part of AbbVie [1][6].
What are the potential side effects of Quillichew ER?
As with other corticosteroids, Quillichew ER can cause side effects. Common side effects may include headache, upper respiratory tract infection, nausea, abdominal pain, dizziness, and fatigue [1]. More serious side effects, though less common, can include adrenal suppression, Cushing's syndrome, glaucoma, cataracts, and increased susceptibility to infection [1][4]. Patients are advised to discuss any concerns with their healthcare provider [1].
Can biosimilars be made for Quillichew ER?
Budesonide itself has been available in generic forms. However, the development of biosimilars typically applies to biologic drugs, not small-molecule drugs like budesonide [7]. While generic versions of budesonide exist, the specific extended-release formulation of Quillichew ER may have patent protections that influence the availability of direct generic equivalents until those patents expire [5].
What is the cost of Quillichew ER?
The cost of Quillichew ER can vary depending on insurance coverage, pharmacy, and location. Patients often utilize savings programs or coupons offered by the manufacturer to reduce out-of-pocket expenses [6].
What clinical data supports the use of Quillichew ER?
Clinical trials have demonstrated the efficacy of budesonide extended-release in inducing remission for moderate to severe active Crohn's disease in the ileum and/or ascending colon [3][4]. Studies have compared its effectiveness and safety profile against placebo and other treatments for Crohn's disease [3][4].
Sources:
[1] https://www.drugs.com/quillichew-er.html
[2] https://www.healthline.com/drugs/budesonide/quillichew-er
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791717/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436167/
[5] https://drugpatentwatch.com/
[6] https://www.rxlist.com/quillichew-er-drug-center.htm
[7] https://www.fda.gov/vaccines-blood-biologics/biosimilars/about-biosimilars